Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial

Edgard Dabira; Hamtandi Natama; Fatou Jaiteh; Koen Grietens; Fadima Bocoum; Mamadou Ndiath; Nuredin Mohammed; Balla Gibba; Adrian Hill; Azra Ghani; Annette Erhart; Halidou Tinto; Umberto D’Alessandro

doi:10.21203/rs.3.rs-6292533/v1

Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial

Edgard Dabira
, Hamtandi Natama
, Fatou Jaiteh
, Koen Grietens
, Fadima Bocoum
, Mamadou Ndiath
, Nuredin Mohammed
, Balla Gibba
, Adrian Hill
, Azra Ghani
, Annette Erhart
, Halidou Tinto
, Umberto D’Alessandro

Socio-ecological Health Research

Research output: Working paper › Preprint

Abstract

Introduction
Progress in malaria control has stalled since 2015, highlighting the need for new control tools. The R21/Matrix-M (R21) malaria vaccine, a pre-erythrocytic vaccine recently approved by WHO for small children, may be one of these tools. This trial aims to assess whether seasonal mass vaccination with R21 reduces malaria transmission in The Gambia and Burkina Faso, two countries at the extreme of the transmission spectrum.

Methods
This is a multi-centre open cluster-randomised controlled trial to assess the impact of mass vaccination with R21 on malaria transmission and morbidity. The trial will be implemented in eastern Gambia (low to moderate transmission), and Central Burkina Faso (intense transmission). Thirty medium-sized villages in The Gambia and 24 in Burkina Faso will be randomised (1:1) to either intervention or control arm. All eligible residents in intervention villages will receive R21 vaccinations in three-monthly rounds, from May to July 2024, prior to the malaria transmission season. A booster vaccine dose will be administered the following year, in June 2025. The primary outcome is malaria prevalence at peak transmission (November 2024). Secondary outcomes include safety and tolerability, incidence of clinical malaria, vaccination coverage and community acceptability, cost and cost-effectiveness of the intervention.

Discussion
This is the first trial on seasonal mass vaccination aiming at reducing malaria transmission. Strengths of the study include its design as an adequately powered cluster-randomized trial and the inclusion of study sites with differing transmission intensity which will also provide safety and efficacy data for different age groups. Key challenges remain vaccine hesitancy and vaccination coverage. If successful, R21 seasonal mass vaccination will be an innovative intervention to accelerate malaria elimination efforts and reach the goal set in the Global Technical Strategy for malaria 2016-2030.

Trial registration
Clinical trials.gov, NCT06578572. Registered on 27 March 2024

Original language	English
Publisher	Research Square
Number of pages	21
DOIs	https://doi.org/10.21203/rs.3.rs-6292533/v1
Publication status	Published - 22-May-2025

Keywords

Malaria
Vaccination
Medicine
Transmission (telecommunications)
Cluster randomised controlled trial
Malaria vaccine
Environmental health
Cluster (spacecraft)
Randomized controlled trial
Pediatrics
Immunology
Plasmodium falciparum
Surgery

Access to Document

10.21203/rs.3.rs-6292533/v1Licence: CC BY

1 A1: Peer-reviewed journal articles

Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial
Dabira, E., Natama, H., Jaiteh, F., Grietens, K., Bocoum, F., Ndiath, M., Mohammed, N., Gibba, B., Hill, A., Ghani, A., Erhart, A., Tinto, H. & D'Alessandro, U., 29-Sept-2025, In: Trials. 26, 1, 12 p., 382.
Research output: Contribution to journal › A1: Peer-reviewed journal articles › peer-review

Open Access

Cite this

Dabira, E., Natama, H., Jaiteh, F., Grietens, K., Bocoum, F., Ndiath, M., Mohammed, N., Gibba, B., Hill, A., Ghani, A., Erhart, A., Tinto, H., & D’Alessandro, U. (2025). Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial. (Research Square). Research Square. https://doi.org/10.21203/rs.3.rs-6292533/v1

@techreport{9ca8be34630c425580bcbcc5c3d27ee9,

title = "Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial",

abstract = "Introduction Progress in malaria control has stalled since 2015, highlighting the need for new control tools. The R21/Matrix-M (R21) malaria vaccine, a pre-erythrocytic vaccine recently approved by WHO for small children, may be one of these tools. This trial aims to assess whether seasonal mass vaccination with R21 reduces malaria transmission in The Gambia and Burkina Faso, two countries at the extreme of the transmission spectrum. Methods This is a multi-centre open cluster-randomised controlled trial to assess the impact of mass vaccination with R21 on malaria transmission and morbidity. The trial will be implemented in eastern Gambia (low to moderate transmission), and Central Burkina Faso (intense transmission). Thirty medium-sized villages in The Gambia and 24 in Burkina Faso will be randomised (1:1) to either intervention or control arm. All eligible residents in intervention villages will receive R21 vaccinations in three-monthly rounds, from May to July 2024, prior to the malaria transmission season. A booster vaccine dose will be administered the following year, in June 2025. The primary outcome is malaria prevalence at peak transmission (November 2024). Secondary outcomes include safety and tolerability, incidence of clinical malaria, vaccination coverage and community acceptability, cost and cost-effectiveness of the intervention. Discussion This is the first trial on seasonal mass vaccination aiming at reducing malaria transmission. Strengths of the study include its design as an adequately powered cluster-randomized trial and the inclusion of study sites with differing transmission intensity which will also provide safety and efficacy data for different age groups. Key challenges remain vaccine hesitancy and vaccination coverage. If successful, R21 seasonal mass vaccination will be an innovative intervention to accelerate malaria elimination efforts and reach the goal set in the Global Technical Strategy for malaria 2016-2030. Trial registration Clinical trials.gov, NCT06578572. Registered on 27 March 2024",

keywords = "Malaria, Vaccination, Medicine, Transmission (telecommunications), Cluster randomised controlled trial, Malaria vaccine, Environmental health, Cluster (spacecraft), Randomized controlled trial, Pediatrics, Immunology, Plasmodium falciparum, Surgery",

author = "Edgard Dabira and Hamtandi Natama and Fatou Jaiteh and Koen Grietens and Fadima Bocoum and Mamadou Ndiath and Nuredin Mohammed and Balla Gibba and Adrian Hill and Azra Ghani and Annette Erhart and Halidou Tinto and Umberto D{\textquoteright}Alessandro",

note = "FTX: CC BY",

year = "2025",

month = may,

day = "22",

doi = "10.21203/rs.3.rs-6292533/v1",

language = "English",

series = "Research Square",

publisher = "Research Square",

type = "WorkingPaper",

institution = "Research Square",

}

TY - UNPB

T1 - Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial

AU - Dabira, Edgard

AU - Natama, Hamtandi

AU - Jaiteh, Fatou

AU - Grietens, Koen

AU - Bocoum, Fadima

AU - Ndiath, Mamadou

AU - Mohammed, Nuredin

AU - Gibba, Balla

AU - Hill, Adrian

AU - Ghani, Azra

AU - Erhart, Annette

AU - Tinto, Halidou

AU - D’Alessandro, Umberto

N1 - FTX: CC BY

PY - 2025/5/22

Y1 - 2025/5/22

N2 - Introduction Progress in malaria control has stalled since 2015, highlighting the need for new control tools. The R21/Matrix-M (R21) malaria vaccine, a pre-erythrocytic vaccine recently approved by WHO for small children, may be one of these tools. This trial aims to assess whether seasonal mass vaccination with R21 reduces malaria transmission in The Gambia and Burkina Faso, two countries at the extreme of the transmission spectrum. Methods This is a multi-centre open cluster-randomised controlled trial to assess the impact of mass vaccination with R21 on malaria transmission and morbidity. The trial will be implemented in eastern Gambia (low to moderate transmission), and Central Burkina Faso (intense transmission). Thirty medium-sized villages in The Gambia and 24 in Burkina Faso will be randomised (1:1) to either intervention or control arm. All eligible residents in intervention villages will receive R21 vaccinations in three-monthly rounds, from May to July 2024, prior to the malaria transmission season. A booster vaccine dose will be administered the following year, in June 2025. The primary outcome is malaria prevalence at peak transmission (November 2024). Secondary outcomes include safety and tolerability, incidence of clinical malaria, vaccination coverage and community acceptability, cost and cost-effectiveness of the intervention. Discussion This is the first trial on seasonal mass vaccination aiming at reducing malaria transmission. Strengths of the study include its design as an adequately powered cluster-randomized trial and the inclusion of study sites with differing transmission intensity which will also provide safety and efficacy data for different age groups. Key challenges remain vaccine hesitancy and vaccination coverage. If successful, R21 seasonal mass vaccination will be an innovative intervention to accelerate malaria elimination efforts and reach the goal set in the Global Technical Strategy for malaria 2016-2030. Trial registration Clinical trials.gov, NCT06578572. Registered on 27 March 2024

AB - Introduction Progress in malaria control has stalled since 2015, highlighting the need for new control tools. The R21/Matrix-M (R21) malaria vaccine, a pre-erythrocytic vaccine recently approved by WHO for small children, may be one of these tools. This trial aims to assess whether seasonal mass vaccination with R21 reduces malaria transmission in The Gambia and Burkina Faso, two countries at the extreme of the transmission spectrum. Methods This is a multi-centre open cluster-randomised controlled trial to assess the impact of mass vaccination with R21 on malaria transmission and morbidity. The trial will be implemented in eastern Gambia (low to moderate transmission), and Central Burkina Faso (intense transmission). Thirty medium-sized villages in The Gambia and 24 in Burkina Faso will be randomised (1:1) to either intervention or control arm. All eligible residents in intervention villages will receive R21 vaccinations in three-monthly rounds, from May to July 2024, prior to the malaria transmission season. A booster vaccine dose will be administered the following year, in June 2025. The primary outcome is malaria prevalence at peak transmission (November 2024). Secondary outcomes include safety and tolerability, incidence of clinical malaria, vaccination coverage and community acceptability, cost and cost-effectiveness of the intervention. Discussion This is the first trial on seasonal mass vaccination aiming at reducing malaria transmission. Strengths of the study include its design as an adequately powered cluster-randomized trial and the inclusion of study sites with differing transmission intensity which will also provide safety and efficacy data for different age groups. Key challenges remain vaccine hesitancy and vaccination coverage. If successful, R21 seasonal mass vaccination will be an innovative intervention to accelerate malaria elimination efforts and reach the goal set in the Global Technical Strategy for malaria 2016-2030. Trial registration Clinical trials.gov, NCT06578572. Registered on 27 March 2024

KW - Malaria

KW - Vaccination

KW - Medicine

KW - Transmission (telecommunications)

KW - Cluster randomised controlled trial

KW - Malaria vaccine

KW - Environmental health

KW - Cluster (spacecraft)

KW - Randomized controlled trial

KW - Pediatrics

KW - Immunology

KW - Plasmodium falciparum

KW - Surgery

U2 - 10.21203/rs.3.rs-6292533/v1

DO - 10.21203/rs.3.rs-6292533/v1

M3 - Preprint

T3 - Research Square

BT - Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial

PB - Research Square

ER -

Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial

Abstract

Keywords

Access to Document

Fingerprint

Research output

Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial

Cite this